Targeting Myeloma Bone Disease via Activin A Inhibition

被引：0
|
作者：
Vallet, S. [1 ]
Mukherjee, S. [1 ]
Vaghela, N. [1 ]
Pozzi, S. [1 ]
Santo, L. [2 ]
Cirstea, D. [2 ]
Fulciniti, M. [3 ]
Rahemtullah, A. [1 ]
Attar, E. [1 ]
Xie, W. [2 ]
Patel, C. [1 ]
Schoonmaker, J. A. [1 ]
Weller, E. [2 ]
Hideshima, T. [2 ]
Munshi, N. C. [3 ]
Seehra, J. S. [4 ]
Scadden, D. T. [1 ]
Anderson, K. C. [2 ]
Raje, N. [1 ]
机构：
[1] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, VA Boston Hlth Care Syst, Boston, MA USA
[4] Acceleron Pharma Inc, Cambridge, MA USA
来源：
CLINICAL LYMPHOMA & MYELOMA | 2009年 / 9卷
关键词：
D O I：
10.1016/S1557-9190(11)70715-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S126 / S127
页数：2
相关论文
共 50 条
  • [1] Restoration of Bone Balance Via Activin a Inhibition Results in Anti-Myeloma Activity
    Vallet, Sonia
    Mukherjee, Siddhartha
    Vaghela, Nileshwari
    Pozzi, Samantha
    Santo, Loredana
    Cirstea, Diana
    Fulciniti, Mariateresa
    Rahemtullah, Aliyah
    Attar, Eyal
    Guimaraes, Alexander R.
    Xie, Wanling
    Patel, Chirayu
    Schoonmaker, Jesse
    Weller, Edie
    Hideshima, Teru
    Munshi, Nilchil C.
    Seehra, Jas
    Scadden, David T.
    Anderson, Kenneth C.
    Raje, Noopur
    BLOOD, 2008, 112 (11) : 240 - 240
  • [2] A soluble activin type II receptor prevents myeloma bone disease
    Chantry, A. D.
    Heath, D.
    Coulton, L.
    Gallagher, O.
    Evans, H.
    Seehra, J.
    Vanderkerken, K.
    Croucher, P. I.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 (07) : 1118 - 1118
  • [3] A soluble activin type II receptor prevents myeloma bone disease
    Chantry, A.
    Heath, D.
    Coulton, L.
    Gallagher, O.
    Evans, H.
    Seehra, J.
    Vanderkerken, K.
    Croucher, P. I.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 133 - 133
  • [4] Targeting host factors in myeloma bone disease
    Roodman, G. D.
    CANCER TREATMENT REVIEWS, 2006, 32 : S23 - S24
  • [5] New agents targeting myeloma bone disease
    Roodman, G. D.
    Kurihara, N.
    Hiruma, Y.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 20 - 20
  • [6] Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
    Vallet, Sonia
    Mukherjee, Siddhartha
    Vaghela, Nileshwari
    Hideshima, Teru
    Fulciniti, Mariateresa
    Pozzi, Samantha
    Santo, Loredana
    Cirstea, Diana
    Patel, Kishan
    Sohani, Aliyah R.
    Guimaraes, Alex
    Xie, Wanling
    Chauhan, Dharminder
    Schoonmaker, Jesse A.
    Attar, Eyal
    Churchill, Michael
    Weller, Edie
    Munshi, Nikhil
    Seehra, Jasbir S.
    Weissleder, Ralph
    Anderson, Kenneth C.
    Scadden, David T.
    Raje, Noopur
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (11) : 5124 - 5129
  • [7] A soluble activin type II receptor prevents the development of myeloma bone disease
    Chantry, Andre
    Heath, Deborah
    Coutton, Les
    Evans, Hotly
    Abdul, Nicole
    Seehra, Jas
    Vanderkerken, Karin
    Croucher, Peter
    CANCER TREATMENT REVIEWS, 2008, 34 : S56 - S57
  • [8] Activin A Mediates Multiple Myeloma (MM) Bone Disease which Is Reversed by RAP-011. a Soluble Activin Receptor
    Vallet, S.
    Mukherjee, S.
    Vaghela, N.
    Hideshima, T.
    Pozzi, S.
    Santo, L.
    Cirstea, D.
    Seehra, J.
    Scadden, D. T.
    Anderson, K. C.
    Raje, N.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S65 - S65
  • [9] Multiple myeloma bone disease: pathophysiology of osteoblast inhibition
    Giuliani, Nicola
    Rizzoli, Vittorio
    Roodman, G. David
    BLOOD, 2006, 108 (13) : 3992 - 3996
  • [10] Myeloma bone-disease and proteasome inhibition therapies
    Terpos, Evangelos
    Sezer, Orhan
    Croucher, Peter
    Dimopoulos, Meletios-Athanassios
    BLOOD, 2007, 110 (04) : 1098 - 1104
12345